Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Fineline Cube Aug 13, 2026
Company Deals

Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002

Fineline Cube Aug 13, 2026
Company Deals

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

Fineline Cube Aug 13, 2026
Company Deals

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

Fineline Cube Aug 13, 2026
Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

Fineline Cube Aug 13, 2026
Company Drug

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

Fineline Cube Aug 13, 2026
Company Drug

Telix Pharmaceuticals’ TLX591-CDx Approved in Europe via Decentralized Procedure

Fineline Cube Jan 17, 2025

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that the marketing filing in Europe via...

Policy / Regulatory

NMPA Implements Regulatory Reforms for Drug and Medical Device Industries

Fineline Cube Jan 17, 2025

The National Medical Products Administration (NMPA) has released a notification regarding the implementation of the...

Company Deals Drug

Daiichi Sankyo Acquires Gatipotuzumab IP Rights for $132.5M

Fineline Cube Jan 17, 2025

Japan-based Daiichi Sankyo Company, Ltd (TYO: 4568) has announced an investment of USD 132.5 million...

Policy / Regulatory

NHSA Pushes for Real-Time Settlement Reform in Basic Medical Insurance

Fineline Cube Jan 17, 2025

The National Healthcare Security Administration (NHSA) has released a notification to promote the real-time settlement...

Company Deals

a16z Bio + Health Launches Biotech Ecosystem Venture Fund

Fineline Cube Jan 17, 2025

Andreessen Horowitz (a16z) Bio + Health has announced the establishment of the Biotech Ecosystem Venture...

Company Drug

Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy

Fineline Cube Jan 17, 2025

China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...

Company

Siemens Lays Foundation for New Medical Equipment Base in Shenzhen

Fineline Cube Jan 17, 2025

Siemens (Shenzhen) Magnetic Resonance Co., Ltd., a wholly-owned subsidiary of Siemens Ltd., China, has officially...

Company Deals

Fujian Haixi Pharmaceuticals Files for Hong Kong IPO

Fineline Cube Jan 17, 2025

China-based Fujian Haixi Pharmaceuticals Co., Ltd., a commercial-stage innovative pharmaceutical company, has made an initial...

Company Drug

SciClone and Menarini Submit NDA for Vaborem in China

Fineline Cube Jan 17, 2025

China-based SciClone Pharmaceuticals Inc and its Italy-based strategic partner Menarini have announced the submission of...

Company Deals

Servier and Google Cloud Extend Partnership to Advance AI in Drug Development

Fineline Cube Jan 17, 2025

France-based Servier Group and US technology firm Google Cloud have announced an expansion to their...

Company Deals

Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials

Fineline Cube Jan 17, 2025

Shanghai-based Cathay Biotech Inc. (SHA: 688065) has announced plans to raise RMB 6.6 billion (USD...

Company Deals

Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037

Fineline Cube Jan 17, 2025

China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm...

Company Medical Device

Boston Scientific’s FARAPULSE and WATCHMAN FLX Studies Show Positive Results

Fineline Cube Jan 17, 2025

US major Boston Scientific Corporation (NYSE: BSX) has announced the presentation of positive results from...

Company Drug

Asieris’ USP1 Inhibitor APL-2302 Cleared for Clinical Trials

Fineline Cube Jan 17, 2025

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced receiving clinical clearance from the...

Company Drug

Zhejiang Huahai’s HB0056 Approved for US Phase I Asthma Trial

Fineline Cube Jan 17, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval from...

Company Drug

Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials

Fineline Cube Jan 17, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...

Company Drug

CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials

Fineline Cube Jan 17, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...

Company Drug

Innovent’s Limertinib Wins NMPA Approval for NSCLC Treatment

Fineline Cube Jan 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that it has received New Drug Application...

Company

ConjuStar Completes $15 Million Pre-A+ Financing Round

Fineline Cube Jan 17, 2025

ConjuStar, a clinical-stage biotechnology company based in Tianjin, China, has announced the completion of a...

Company Deals

Bio-Thera Solutions Licenses BAT2206 to World Medicine for Turkey

Fineline Cube Jan 16, 2025

On January 16, Bio-Thera Solutions Ltd (SHA: 688177), a science – driven innovative global biopharmaceutical...

Posts pagination

1 … 267 268 269 … 708

Recent updates

  • AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab
  • Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease
  • Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China
  • IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform
  • Akeso’s Ivonescimab Wins NMPA Approval for First-Line Advanced Squamous Non-Small Cell Lung Cancer in Combination With Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

Company Drug

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

Company Deals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Company Drug

IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.